Biotech Consulting & Cross-Border Pharma Advisory.
Life science consulting for licensing, M&A, partnerships, and deal-making across global pharma and biotech.
The next generation of medicines will be built by partnerships that move across borders – not by programs that stay inside them.
PharmaSync
Strategic advisory across the full deal lifecycle.
From first asset screen to signed agreement, we run the work end to end – sourcing, diligence, structuring, and negotiation under one senior team.
In-Licensing
Acquire rights to differentiated therapeutics and platform technologies from sources around the world.
- Asset sourcing
- Scientific diligence
- Deal execution
Out-Licensing
Position differentiated programs in front of qualified strategic buyers and development partners.
- Buyer mapping
- Package preparation
- Terms negotiation
Strategic Partnerships
Construct alliances for development, manufacturing, and commercialization across markets.
- Co-development
- Cross-border manufacturing
- Joint commercialization
NewCo Formation
Spin assets into independent companies backed by global capital and dedicated focus.
- Carve-out structuring
- Capital syndication
- Governance design
Where our network runs deepest.
We work modality-agnostic, but our relationships and diligence sharpen fastest in the areas where cross-border value moves most.
A specialist advisor for life-science deal-making.
We are built for one job – moving complex cross-border transactions from scientific signal to signed agreement, with senior people accountable at every stage.
Global Network
Direct, warm relationships with strategics, investors, and innovators across Asia, Europe, and the United States.
Asset Expertise
Scientific and commercial diligence that reads a data package the way a sophisticated buyer will.
Deal Experience
Decades of structuring, terms, and negotiation across licensing, partnerships, M&A, and NewCo formation.
End-to-End Support
One team from first call to close – no handoffs, no junior-led process, no dropped threads.
Scope of engagement.
We take a defined set of cross-border mandates and run them with senior ownership – structured for the relationship that has to survive long after signatures.
Licensing · M&A · Partnerships · NewCo
Buy-side and sell-side, end to end.
Oncology · Immunology · Metabolic · CNS · Rare
Modality-agnostic – small molecule to cell & gene.
$25M – $1B+ in committed economics
Bespoke structures, not a fee table.
4–9 months · term-sheet to close
Partner-led from first call through close.
Selected thinking from the desk.
Pharma deal intelligence, delivered.
Cross-border deal signals, monthly.
A monthly read on the licensing, partnership, and NewCo moves shaping value across our corridor – written for people who do these deals.
Every cross-border deal that mattered, in five minutes.
A tight weekly digest of the transactions, terms, and partnerships worth your attention – no noise, no filler.